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Background 
Acid suppressive drugs, one of the most 
frequently prescribed drug classes, continue to 
grow in sales.1  Yet their use is not without risk.2 
The normal pH of the stomach is a host 
defense and barrier to ingested pathogens.3  
Bacterial overgrowth and colonization with upper 
gastrointestinal tract bacteria have been identified 
in studies with acid-inhibitory therapy.3,4  Acid-
suppressing drugs are associated with bacterial 
overgrowth in the stomach and influenza viruses 
in the gastric mucosa.3,5  Studies have also shown 
that bacterial overgrowth depends on the intensity 
of inhibition of gastric acid secretion and 
corresponding increase in pH.  Both H2 receptor 
antagonists (H2RAs) and proton pump inhibitors 
(PPIs) effectively raise gastric pH.  Proton pump 
inhibitors have greater inhibition of gastric acid 
secretion compared with H2 receptor 
antagonists.4,6 
Colonized oral secretions can be aspirated into 
the lungs and establish pneumonia.7   
 
Citation 
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Methods 
Complete medical records for approximately 
half a million patients were accessed from the 
Integrated Primary Care Information project, a 
Dutch general practice research database.  The 
seven-year study included all patients with at least 
a one-year recorded history.  All participants were 
followed once they had a one-year history until 
the study ended, or until they had pneumonia, 
died, or moved out of the practice area.  All those 
with a pre-study pneumonia diagnosis were 
excluded.  All patients exposed to acid-
suppressive therapy were compared to those who 
did not receive this therapy in the study period 
relative to their incidence of community-acquired 
pneumonia.  Incidence rates were calculated for 
exposed and unexposed participants.  To prevent 
confounding by antagonist indication, a nested 
case-control analysis of patients with pneumonia 
and using acid-suppressive drugs prior to or at the 
time of contracting pneumonia was conducted.   
 
Results 
A total of 364,683 suppressive therapy 
exposed and unexposed patients were identified.  
Person-time of exposure was calculated on the 
basis of person-years.  Overall, 5.3% of these 
individuals were exposed to suppressive drugs.  
This represented 7562 person-years.  During the 
study period, 185 cases of radiographic or sputum 
culture confirmed-pneumonia occurred.  The 
incidence rate of pneumonia in acid-suppressive 
users was 2.45 and for non-suppressive 
participants the rate was 0.6 per 100 person-years. 
The adjusted relative risk for pneumonia for those 
currently using PPIs compared with those who 
stopped using PPIs was 1.89 (95% confidence 
interval, 1.36 to 2.62).  H2RA current users had a 
1.63 adjusted relative risk for pneumonia (95% 
confidence interval, 1.07 to 2.48) compared with 
those who stopped their use.   
A significant dose response was observed in 
PPI users taking more than one dose per day.  
They had a 2.3-fold increased risk of pneumonia 
compared with past acid-suppressive drug users.  
This dose response was not observed with H2RAs.   
 
Author Conclusions 
Both H2RA and PPI acid-suppressive drugs are 
associated with an increase in community-
acquired pneumonia risk.  This association 
probably results from their effective suppression 
of gastric pH which facilitates opportunistic 
infection by intestinal bacterial and viral 
organisms.  
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Commentary 
The availability of acid-suppressive therapy is 
a major factor in the effective treatment of 
gastrointestinal ulcerative disease.  The rational 
use of these agents is associated with both 
efficacy and safety.  They represent a major 
milestone for improvement of the quality of life in 
patients suffering from these common disorders. 
As demonstrated in this study, despite their 
safety and efficacy, acid-suppressive agents can 
present risk for certain patients.   
In another study of 700 patients by Laheij RJ, 
et al, those using acid-suppressive drugs were 
2.34 times more likely (95% confidence interval, 
1.4 to 4.1) than non-suppressive users to have 
clinical signs of infection.  They also visited a 
physician 3.72 times more often (95% confidence 
interval, 2.1 to 6.8) for an infection and received 
an antibiotic 4.19 times more often (95% 
confidence interval, 2.2 to 8.1) compared with 
non-suppressive users.8 
In a recent investigation, both cohort and case-
controlled studies were undertaken to assess acid-
suppressive therapy as a risk factor for C. difficile 
infection.  C. difficile diarrhea developed in 6.8% 
of the 1,187 cohort patients.  Of the patients who 
received antibiotics and a PPI, 9.3% developed C. 
difficile diarrhea, whereas those who received 
antibiotics but no PPI experienced a 4.4% 
incidence (RR 2.1, 95% CI 1.4 to 3.4).  The 
relative risk of C. difficile was higher in patients 
receiving PPIs compared with H2RA recipients 
(OR 2.1, 95% CI 1.2 to 3.5 vs. OR 1.1, 95% CI 
0.4 to 3.4).9   
In the case-control study, 94 patients 
developed C. difficile diarrhea.  The case and 
control subjects were similar in age, number and 
type of antibiotic, and comorbidity factors.  Of the 
cases, 64% were receiving PPIs as compared with 
36% of the controls (unadjusted OR 3.1, 95% CI 
1.7 to 5.6).9  
These authors concluded that patients 
receiving PPIs were at greater risk for C. difficile 
diarrhea.9 
Given these concerns associated with acid-
suppressive therapy, at-risk patients should be 
identified.  Community-acquired pneumonia is a 
danger for those who are generally at risk for 
infection.10  At risk groups include those with 
asthma, chronic obstructive pulmonary disease, 
children, the elderly, and those who are 
immunocompromised.11  In these at risk groups, 
patients needing acid-suppressive therapy may 
benefit from sucralfate (Carafate) which does not 
appear to affect gastric acid concentration.12 
Evidence presented in this study suggests that 
patients should be treated with acid-suppressing 
drugs only when necessary and at the lowest 
effective dose [Evidence level B, epidemiologic 
study, clinical cohort study].2 
 
 
 
Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
article were current as of the date of publication. 
 
Levels of Evidence 
In accordance with the trend towards Evidence-Based 
Medicine, we are citing the LEVEL OF EVIDENCE 
for the statements we publish. 
 
Level Definition 
A High-quality randomized controlled trial (RCT) 
 High-quality meta-analysis (quantitative 
systematic review) 
B Nonrandomized clinical trial 
 Nonquantitative systematic review 
 Lower quality RCT 
 Clinical cohort study 
 Case-control study 
 Historical control 
 Epidemiologic study 
C Consensus 
 Expert opinion 
D Anecdotal evidence 
In vitro or animal study 
Adapted from Siwek J, et al.  How to write an evidence-based 
clinical review article.  Am Fam Physician 2002;65:251-8. 
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